By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Galderma Laboratories 

14501 N. Freeway

Fort Worth  Texas  76177  U.S.A.
Phone: 817-961-5000 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
Ipsen (IPN.PA) And Galderma Laboratories Become Exclusive Partners For Development And Marketing Of Neurotoxins In The US, Canada, Brazil And Europe 7/11/2014 9:08:57 AM
Galderma Laboratories Unites With Hit Music Artists And PACERā€™S National Bullying Prevention Center To Raise The Volume Around Bullying Prevention 7/8/2014 6:58:45 AM
Galderma Laboratories To Gain Rights To Restylane, Perlane, Sculptra And Dysport In The United States And Canada 5/28/2014 11:55:13 AM
Galderma Laboratories Announces Positive Results Of Phase 3 Trials Of Investigational Ivermectin 1% Targeting Papulopustular Rosacea 3/24/2014 7:30:20 AM
Bioventus Acquires DUROLANEĀ® Assets From Galderma 2/4/2014 9:35:19 AM
Galderma Laboratories Slashes U.S. Staff After President's Exit 12/13/2013 8:10:13 AM
Onset Dermatologics (Formerly known as Onset Therapeutics) Acquires Worldwide Rights to Clindagel® (clindamycin phosphate gel) Topical Gel, 1% From Galderma Laboratories 10/31/2013 12:29:49 PM
Galderma Laboratories Serves as Premier Sponsor for 2013 Commit to Cure Gala Benefitting National Psoriasis Foundation 10/21/2013 8:05:34 AM
Galderma Laboratories Release: Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship 9/11/2013 9:27:51 AM
Galderma Laboratories Receives FDA Approval of Mirvaso®: the First and Only FDA-Approved Topical Treatment Specifically Developed and Indicated for the Facial Erythema of Rosacea 8/26/2013 6:57:46 AM
123456
//-->